On this page
When the scale stops moving on a GLP-1, it usually doesn’t mean the medicine quit. Your body may have reached a new balance point. The answer starts with a look at your dose, how you’re taking it, what you’re eating, your other medicines, and what you expected. A plateau isn’t a failure, and it doesn’t automatically mean a higher dose.
First, make sure it’s a real plateau. That means six weeks or more with no change on the scale, the tape measure, and in how your clothes fit. Two flat weeks on the scale alone doesn’t count, because weight goes up and down day to day. The six-week mark is a common rule of thumb, and no trial has tested it.
Why the scale stops
Semaglutide and tirzepatide act on the parts of your brain that control appetite. They also slow gastric emptying (how fast food leaves your stomach), which keeps you full longer, and they help your body release insulin. Tirzepatide works on one more hormone, called GIP.
So you eat less. But a smaller body burns less energy, so the gap between what you eat and what you burn shrinks as the weight comes off. When the two match, the scale stops. Every obesity treatment that works ends this way, and the only question is where you land.
In STEP 1 (Wilding et al., NEJM 2021), 1,961 adults with obesity and no diabetes took brand-name semaglutide (Wegovy) 2.4 mg weekly. After 68 weeks they had lost 14.9% of their body weight on average, compared with 2.4% on placebo. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), 2,539 adults took brand-name tirzepatide (Zepbound) for 72 weeks. Average loss was 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, compared with 3.1% on placebo.
Say you lost 14% on semaglutide and then stalled. That’s just under the trial average, so it isn’t a failure. The real question is whether there’s anything left you haven’t tried.
Check the dose before you blame the medicine
A semaglutide dose goes up in steps on a schedule your clinician sets, and it can go slower if side effects get in the way. If you stalled partway up, you haven’t hit your top dose yet.
A higher dose may be one option, but it isn’t automatic. Your clinician will also check whether you’ve missed doses, how you’re eating, and whether another medicine or health problem is in play.
At Zappy, a US-licensed clinician looks at every case and adjusts your titration (the schedule for raising your dose). Our compounded semaglutide and tirzepatide come from LegitScript-verified 503A US pharmacies. Compounded medicines are not FDA-approved.
Nausea after a dose increase is common, and there’s a reason for it. Because these drugs slow your stomach, nausea tends to arrive with each dose increase and fade once the dose holds steady. If you’re vomiting and can’t keep up with it, call your clinician, because that changes the dose plan.
Take an honest look at your habits
Protein, plus strength training twice a week. A range often cited is 1.2–1.6 g/kg per day, but ask your clinician for your own target. This problem has been measured. Body-composition scans (called DXA) from the GLP-1 trials show that a real share of the weight people lose is lean mass, which includes muscle. Experts agree on how to push back: eat enough protein and do strength training. Does losing that lean mass hurt strength or daily function years later? We don’t know yet. (Twice a week is our practical minimum, and no trial tested that exact amount.)
Sleep and alcohol. No plateau trial has tested either one. But alcohol adds calories and makes sleep worse, and both are easy to check before anyone changes a prescription. This part is our judgment, with no trial data behind it.
The one move that reliably backfires
Quitting at the plateau. Two trials tested what happens when people stop.
In STEP 4 (Rubino et al., JAMA 2021), some people stopped brand-name semaglutide (Wegovy) at week 20 and gained back a lot of weight, while people who kept going held on to their loss. Stopping without a maintenance plan usually undoes the loss.
In SURMOUNT-4 (Aronne et al., JAMA 2024), everyone took brand-name tirzepatide (Zepbound) for 36 weeks before some were switched to placebo. Over the next year, that group gained back about 14% of their body weight, while the people who kept taking it lost about 5.5% more. So staying on past week 36 still led to more loss, which means flat weeks don’t prove the drug stopped working.
The scale isn’t the only thing that counts. SELECT (Lincoff et al., NEJM 2023) studied 17,604 adults with overweight or obesity who already had cardiovascular disease and no diabetes. Brand-name semaglutide (Wegovy) 2.4 mg lowered their risk of major heart events, like heart attack and stroke, by 20% in relative terms (HR 0.80). That’s a relative number in a high-risk group. But if you have heart disease, it belongs in your stay-or-stop decision along with the scale.
At full dose and still flat
Maybe you’re at 2.4 mg semaglutide or 15 mg tirzepatide, your habits check out, and six weeks are flat. Two options are left.
One is switching medicines. Comparing STEP 1 with SURMOUNT-1 makes brand-name tirzepatide (Zepbound) look stronger, but those were different trials in different people, and they didn’t test the two drugs against each other. Don’t lean on that comparison too hard. (Semaglutide vs tirzepatide walks through it.)
The other is something else holding you back, like an untreated thyroid problem, a medicine that works against weight loss, or long-term short sleep. This is where talking to your clinician really matters. A thyroid blood test and a review of your medicines can find real problems, and switching medicines is a prescription decision.
What to do this week
- Evidence: A higher dose of brand-name tirzepatide (Zepbound) led to more loss (the dose steps in SURMOUNT-1). Stopping brand-name semaglutide (Wegovy) or Zepbound undid the loss (STEP 4, SURMOUNT-4).
- Expert agreement: enough protein plus strength training, to protect muscle.
- Our opinion: Wait for six flat weeks on all three measures before you call it a plateau, and check your sleep and alcohol before you question the medicine.
The trial nobody has run
No one has taken people on a plateau and randomly assigned them to hold their dose, raise it, or switch drugs. The study that would settle most of this page doesn’t exist. Tapering is the same gap: STEP 4 (brand-name semaglutide, Wegovy) and SURMOUNT-4 (brand-name tirzepatide, Zepbound) tested stopping all at once, and neither tested stepping down slowly. So we really don’t know who could hold their loss on a lower maintenance dose. Until someone runs that trial, handling a plateau means using good judgment on your own chart.
